A Study of Diagnosis and Treatment of Depression Based on Biological Evidence of Dopamine Reward Pathway

Phase 4

• Conditions: Diagnosis and Treatment of Depression
• Interventions: Drug: aripiprazole; Drug: risperidone; Drug: bupropion

• Registration Number: NCT03148509
• Lead Sponsor: Peking University

Brief Summary

This study will recruit depressed patients unresponsive to selective serotonin reuptake inhibitor antidepressant treatment, first-degree relatives (parents or siblings) of depressed patients, schizophrenia, Parkinson's disease with and without depression, and healthy controls. The subjects need to complete the brain positron emission tomography/magnetic resonance examination, stress assessment, genetic testing, clinical evaluation and neuropsychological tests. Using the data, this study aimed to identify the abnormalities of reward circuit of depression and its differences with other diseases, and its abnormalities in first-degree relatives of depression. The depressed patients who were ineffective in treatment with selective serotonin reuptake inhibitor antidepressants were then given combined medication with dopamine receptor-mediated drugs, including dopamine transporter inhibitor - bupropion, D2 receptor antagonist - risperidone, or D2 receptor partial agonist - aripiprazole, to examine the regulation of dopamine pathway and its relationship with the therapeutic effect. Through the above work, we will provide new evidence for integrating the biological evidence of dopamine reward pathway into the clinical practice of depression.

Detailed Description

Not available

Study Timeline

• Status Verified: 2017-05
• Study First Submitted: 2017-05-08
• Study First Submitted QC: 2017-05-09
• Last Update Submitted: 2017-05-10
• Study First Posted: 2017-05-11
• Last Update Posted: 2017-05-12
• Study Start: 2017-06-01
• Primary Completion: 2019-12-30
• Study Completion: 2019-12-30

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 300

Inclusion Criteria

• patients unresponsive to SSRI antidepressant treatment, first-degree relatives (parents or siblings) of depressed patients, schizophrenia, Parkinson's disease with and without depression, and healthy controls

Exclusion Criteria

• Major physical illness; other DSM-IV axis I mental illness; personality disorder, mental retardation; drug and/or alcohol dependence; pregnant or lactating women; MRI examination contraindications.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
risperidone	aripiprazole	receive risperidone
bupropion	risperidone	receive bupropion
aripiprazole	bupropion	receive aripiprazole

Primary Outcome Measures

Name	Time	Method
Hamilton Rating Scale for Depression	8 weeks